Summary & Overview
HCPCS C9610: Coronary Transluminal Drug Delivery Catheter
HCPCS Level II code C9610 denotes an insertable catheter used for transluminal coronary drug delivery, performed with or without angioplasty. This device-level code is relevant to interventional cardiology and device billing, affecting inpatient and outpatient cardiac catheterization billing practices nationwide. The code matters nationally because it captures the use of a specialized catheter for localized pharmacologic therapy in coronary interventions, which can influence device charges, bundling decisions, and payer coverage determinations.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for C9610, the typical sites where the service is provided, and the primary payer landscape. The publication presents benchmarking and policy considerations relevant to hospital outpatient departments and cardiac catheterization labs, including common billing modifiers and payer coverage patterns. It also outlines areas where payers commonly apply medical necessity reviews or device-specific coverage policies.
The report is intended for revenue cycle managers, coding professionals, and clinical leaders seeking clear, national-level context on device coding for coronary transluminal drug delivery. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9610 describes a catheter for transluminal drug delivery with or without angioplasty, coronary, non-laser (insertable). The service involves delivering pharmaceutical agents directly into coronary vasculature via an insertable catheter, and may be performed with or without concurrent coronary angioplasty.
Service Type: Transluminal coronary drug delivery with possible angioplasty
Typical Site of Service: Cardiac catheterization laboratory or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with progressive exertional angina despite optimal medical therapy is evaluated for percutaneous management of focal coronary in-stent restenosis. Coronary angiography demonstrates a localized restenotic lesion in the left anterior descending artery amenable to catheter-based drug delivery with or without adjunctive balloon angioplasty. The patient is consented for a transluminal drug delivery catheter procedure. In the cardiac catheterization laboratory, vascular access is obtained (commonly via the radial or femoral artery), diagnostic coronary angiography is performed, and a guide catheter is used to engage the target coronary ostium. A drug-coated transluminal catheter is advanced across the lesion; local antiproliferative drug is delivered to the vessel wall with or without adjunctive angioplasty/balloon inflation based on operator assessment. Hemostasis is achieved at the access site and the patient is observed in the post-procedure recovery area with telemetry monitoring and post-procedure antiplatelet management per cardiology protocol. Typical facility settings include an outpatient ambulatory surgical center or an inpatient cardiac catheterization laboratory within a hospital.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity substantially exceeds typical for the procedure (document justification). |